
Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.j-bgm.com](http://www.j-bgm.com)

## ORIGINAL ARTICLE

# The anti-osteoporosis effects of CSN1S2 protein of goat milk and yoghurt on a complete Freund's adjuvant-induced rheumatoid arthritis model in rats



Fatchiyah Fatchiyah <sup>a,\*</sup>, Bambang Setiawan <sup>b,d</sup>,  
Suharjono Suharjono <sup>a</sup>, Zairin Noor <sup>c</sup>

<sup>a</sup> Research Group of Smart Molecule of Natural Genetics Resources, and Department of Biology, Faculty of Sciences, Brawijaya University, Malang, East Java, Indonesia

<sup>b</sup> Research Center for Osteoporosis, and Department of Medical Chemistry and Biochemistry, Medical Faculty, Lambung Mangkurat University, Banjarmasin, South Kalimantan, Indonesia

<sup>c</sup> Research Center for Osteoporosis, and Department of Orthopaedics and Traumatology, Ulin General Hospital, Medical Faculty, Lambung Mangkurat University, Banjarmasin, South Kalimantan, Indonesia

Received 18 July 2015; received in revised form 14 September 2015; accepted 7 October 2015

Available online 21 October 2015

## KEYWORDS

bioactive peptide;  
femur;  
hydroxyapatite  
crystal;  
mesostructure;  
osteoporosis

**Abstract** This study aimed to evaluate the anti-osteoporosis effect of CSN1S2 protein from goat milk and yoghurt on a complete Freund's adjuvant (CFA)-induced rheumatoid arthritis (RA) model in rats. Twenty-four rats were randomly divided into six groups: control (untreated) group (C), group treated with CSN1S2 (CM) protein from goat milk, group treated with CSN1S2 protein from goat yoghurt (CY), RA group, RA group treated with CSN1S2 protein from goat milk (RAM), and RA group treated with goat yoghurt (RAY). Mineral elements and mesostructure were analyzed using X-ray fluorescence and scanning electron microscopy. Bone histomorphometry was analyzed using the BoneJ software. One way analysis of variance and Tukey post hoc tests were used to analyze and compare the means of all variables between groups. The phosphorus levels were not significantly different between treatment groups relative to the control group ( $p > 0.05$ ), but were significantly higher in the CM and RAY groups relative to that observed in the CY group ( $p < 0.05$ ). CSN1S2 protein of goat milk repaired the collagen structure in the femur trabecular bone. The trabecular thickness and volume were significantly lower in CM and CY groups relative to the control group ( $p < 0.05$ ). The trabecular volume also decreased significantly in the CM group relative to the control group ( $p < 0.05$ ). The trabecular thickness was significantly lower in the CY group relative to the CM group ( $p < 0.05$ ), but the

\* Corresponding author. Research Group of Smart Molecule of Natural Genetics Resources, Department of Biology, Faculty of Sciences, Brawijaya University, Jl. Veteran Malang, East Java 65145, Indonesia.

E-mail address: [fatchiya@ub.ac.id](mailto:fatchiya@ub.ac.id) (F. Fatchiyah).

<sup>d</sup> These authors contributed equally to this work.

trabecular separation and trabecular volume were significantly greater ( $p < 0.05$ ). The trabecular volumes were significantly elevated in the RAM and RAY groups relative to the CM group ( $p < 0.05$ ). The trabecular thickness was significantly higher in the RAY group relative to the CM and CY groups ( $p < 0.05$ ). CSN1S2 protein of goat milk is better than goat yoghurt in repairing femur crystallization and mesostructure in CFA-induced rheumatoid arthritis in rats.

Copyright © 2016, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Rheumatoid arthritis (RhA) is a chronic inflammatory disease with multiple risk factors. The pathomechanism of RhA is associated with chronic soft-tissue inflammation often followed by bone and cartilage destruction.<sup>1</sup> Bone complications are the major extra-articular complications of RhA and can be described as three different forms: periarticular bone loss, adjacent to the inflamed and swelling joints; bone erosions, which share common mechanisms with the periarticular osteopenia; and systemic osteoporosis.<sup>2</sup> Studies indicated that there is higher frequency of osteoporosis and reduced bone mass in RhA patients, in which the largest effect is found on the hip, as compared to healthy controls.<sup>3–6</sup> There is also a two-fold increase in osteoporosis in female RhA patients ranging in age from 20 years to 70 years,<sup>7</sup> with osteoporosis being one of the determinants of fracture risk. RhA patients have an increased risk of fractures of the hip, vertebrae, and pelvis.<sup>7–9</sup> Studies also suggested that women with early-onset RhA have significantly lower femoral neck and whole-body bone-mineral density (BMD), but have similar lumbar spine BMD as compared with controls. The frequency of bone loss at all sites is significantly greater in women with RhA than that of the controls.<sup>10</sup>

Nutritional disorders affect the pathological condition and long-term outcome of physical functions in RhA. Many studies have reported that malnutrition is a well-recognized symptom associated with RhA.<sup>11</sup> The values of nutritional markers, such as albumin, are low in patients with RhA, owing to malnutrition and excessive protein catabolism triggered by high levels of inflammatory substances.<sup>12</sup> Therefore, the nutritional status may be deeply involved in RhA outcome or symptoms.

Bioactive peptides from milk proteins were included within the primary sequence of native proteins that are hydrolyzed by digestive enzymes and then cleaved and modified to produce an active product as a fragment of specific proteins. Bioactive peptides play important roles as signaling molecules in physiological functions and pathogenesis-related chronic diseases, such as hypertension, diabetes, cancer, and osteoporosis, as well as immunomodulatory, anti-hypertension,<sup>13,14</sup> anti-inflammation,<sup>15</sup> anti-oxidative,<sup>16</sup> and anti-glycosylation<sup>17</sup> molecules. Milk proteins are major suppliers of amino acids and micro-nutrients in young mammals or humans. Milk is also rich in biologically active peptides necessary for health. Bioactive peptides are products of enzymatic fermentation that is an important aspect of dietary proteins and offer adequate

nutritional effects. Many researchers have reported that peptide-derived milk fermentation products, such as yogurt, cheese, or other fermented-foods, display more beneficial biological functions related to cell signaling pathways as compared to peptides from fresh milk.<sup>13,14,18,19</sup> However, the bioactive peptides from fresh milk and yogurt that regulate pathways associated with osteoporosis and RhA remain unclear.

Food-derived bioactive peptides represent a source of health enhancing components that may be incorporated into functional foods and/or used as nutraceuticals.<sup>20</sup> Moreover, milk protein-derived bioactive peptides are health-enhancing components that can be used to reduce the risk of disease or to enhance certain physiological functions.<sup>21</sup> Whole casein and electrophoretic-casein fractions have been shown to exhibit different biological activities, such as immunomodulation.<sup>22,23</sup> Our recent study reported that goat milk has the alpha-S2 casein (CSN1S2), a protein with a molecular weight of 36 kDa, which is not present in bovine milk. We have also determined that this protein contains eight peptides analyzed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry<sup>24</sup>; however, there is no study to evaluate the ability of CSN1S2 protein isolated from goat milk and yoghurt to inhibit femur osteoporosis in RhA. Therefore, this study aimed to evaluate the anti-osteoporosis properties of CSN1S2 protein from goat milk or yoghurt in RhA-associated osteoporosis.

## Materials and Methods

### Animals

Twenty-four 12-week old adult male Wistar rats, weighing 150–200 g, were acclimatized for 1 week to the laboratory conditions prior to experimental manipulation. These animals were purchased from Integrated Research and Testing Laboratory, Gadjah Mada University, Yogyakarta, Indonesia. The animals were exposed to a 12-hour light and 12-hour dark cycle at room temperature of 24°C. They had free access to a standard laboratory diet and water *ad libitum*. The animals were randomly divided into six groups ( $n = 4$  each): control (untreated) group (C), group receiving CSN1S2 protein from goat milk (CM), group receiving CSN1S2 protein from goat yoghurt (CY), RhA group (RA), RhA group receiving CSN1S2 from goat milk (RAM), and RhA group receiving CSN1S2 from goat yoghurt (RAY).

## Freund's adjuvant-induced arthritis in rats

The induction of arthritis in rats was performed according to previous studies with modifications.<sup>19</sup> Adjuvant-induced arthritis in rats was established by a single subcutaneous injection of 100  $\mu$ L of complete Freund's adjuvant (CFA, Sigma—Aldrich, St. Louis, MO, USA). Fourteen days after the first injection, the rats were intradermally injected with 50  $\mu$ L CFA in the lower extremity. Arthritic rats were divided into RA, RAM, and RAY groups, while the rats that did not receive CFA injections were divided into C, CM, and CY groups.

## Preparation and administration of casein

The casein was isolated from milk samples from Etawah goats (250 mL). The milk was heated to a temperature of 40°C prior to addition of glacial acetic acid (5 mL) while stirring until precipitate formation. The precipitate was separated by filtration through a nylon mesh membrane. The protein content was measured using a NanoDrop machine (NanoDrop; Thermo Scientific, Wilmington, DE, USA) and then stored at -20°C if not immediately used. The CSN1S2 protein from goat milk and yoghurt was then orally administrated to the rats by gavage at doses of 2 mL/kg body weight according to a previous study with modification.<sup>25</sup>

## Tissue preparation

At the end of the treatment, all rats were anesthetized with diethyl ether. Both femurs were cut using a bone saw, collected, weighed, and rinsed and cleaned with physiological saline. All femur samples were stored in glutaraldehyde until analysis.

## Femoral bone mineral content

Femoral bone mineral content was analyzed by X-ray fluorescence (XRF) by placing bones in a bone tube and scanning according to manufacturer instructions. The bones were analyzed at 20 kV accelerating voltage (MiniPAL 4; PANalytical, Almelo, The Netherlands).<sup>26</sup>

## Femoral bone hydroxyapatite crystals

Characterization of the X-ray diffraction results was performed using PANalytical X'Pert PRO-MPD (PANalytical B.V., Almelo, Netherlands). Subsequent analysis was performed using the software programs as follows: High Score Plus (PANalytical), Crystal Maker (CrystalMaker Software, Ltd., Begbroke, UK), and DDVIEW (<http://www.icdd.com>), complemented with the latest version of PDF2 (<http://www.icdd.com>). Diffraction spectra were recorded at an angle of 2 $\theta$ , from 20° to 60°, with a Cu-K  $\alpha$  radiation source (wave length = 1.54056 Å, 40 mA, 40 kV) and step size of 0.05°. <sup>26</sup> The lattice parameter of each mineral atomic coordinate was visualized with crystal maker.

## Femur mesostructure

The femur head was cut with a scalpel. For scanning electron microscopy (SEM) evaluation, femurs from all groups were cut vertically at the femoral head, and then the femoral bones were fixed in phosphate-buffered formalin, dehydrated in a graded concentration of ethanol, and coated with gold and palladium. The processed bones were then analyzed at 20 kV accelerating voltages by SEM (Inspect TM S50; FEI, Hillsboro, OR, USA).<sup>26</sup>

## Femur histomorphometry

Histomorphometric measurements were carried out according to methods from a previous study with modifications.<sup>27</sup> The measurements at the femur were performed at 500 $\times$  objective magnification using a SEM (FEI), and then the data were analyzed by an image analyzer BoneJ (<http://bonej.org/>). The parameters measured in this study were trabecular number, trabecular separation, trabecular bone volume, and trabecular thickness. Trabecular number (Tb.N, expressed per millimeter) and trabecular separation (Tb.Sp, expressed per micrometer) were calculated assuming that the trabecular bone could be modeled by the parallel plates and bar model ( $Tb.N = Tb.Ar / 10 / Tb.Th$ ;  $Tb.Sp = 1000 / Tb.N - Tb.Th$ ). Trabecular bone volume (BV/TV) is the amount of trabecular bone within the spongy space (expressed as a percentage). Trabecular thickness (Tb.Th, expressed in micrometers) was derived from trabecular perimeter (B.Pm) and trabecular area (B.Ar) ( $Tb.Th = 1.99 B.Ar / 2 / B.Pm$ ).<sup>28</sup>

## Ethics

This study has been evaluated and approved by the research ethics committee of Faculty of Sciences, Universitas Brawijaya, Malang, East Java, Indonesia (Registration number, KEP-90-UB).

## Statistical analysis

Data are presented as mean  $\pm$  SD and differences between groups were analyzed using one way analysis of variance and the Tukey post hoc test with SPSS 16.0 statistical package (SPSS, Inc., Chicago, IL, USA). A *p* value < 0.05 was considered statistically significant.

## Results

### Mineral composition of CSN1S2 protein isolated from goat milk and yoghurt

There were several inorganic compounds found in the CSN1S2 protein from goat milk and yoghurt, including phosphorus, sodium, calcium, iron, nickel, copper, and ytterbium. The CSN1S2 protein from goat yoghurt had lower levels of calcium and nickel, but higher levels of phosphorus as compared to the CSN1S2 protein from goat milk (Table 1).

**Table 1** Mineral content in the CSN1S2 protein from milk and yoghurt.

Mineral contents (%)	CSN1S2-milk	CSN1S2-yoghurt
Phosphorus	5.1 ± 0.3	4.6 ± 0.1
Sodium	15.0 ± 0.4	16.0 ± 0.3
Calcium	39.0 ± 0.8	52.4 ± 0.5
Iron	6.6 ± 0.07	7.0 ± 0.1
Nickel	3.0 ± 0.2	7.1 ± 0.4
Copper	12.0 ± 0.3	13.0 ± 0.2
Ytterbium	19.0 ± 1	0.0 ± 0.0

Data are presented as mean ± standard deviation.

## Femoral bone mineral content

**Table 2** presents the femoral bone mineral content for each group. The levels of calcium, chromium, iron, copper, zinc, nickel, and ytterbium were not significantly different between groups ( $p > 0.05$ ). The phosphorus level in the CY group was significantly lower as compared to the CM group ( $p < 0.05$ ). The phosphorus level was also significantly higher in the RAY group relative to the CY group ( $p < 0.05$ ).

## Femoral bone hydroxyapatite crystal

**Figure 1** shows the crystal size and lattice parameters. The crystal size was increased in the RA group and all treated groups as compared to the control (untreated) group. The lattice parameters were different between groups. The crystallinity was significantly higher in the CM, CY, RAM, and RAY groups relative to the control (untreated) group ( $p < 0.05$ ). However, the crystallinity was not significantly different in the RA group as compared to the control group ( $p > 0.05$ ). Inclusion of the CSN1S2 protein from goat milk and yoghurt significantly increased the crystallinity relative to the control (untreated) or RA groups ( $p < 0.05$ ; **Figure 2**).

## Femur mesostructure

The SEM results for the femur from the control (untreated) group showed a step-ladder pattern of collagen with

granule formations covering the fibrillar collagen. In RA rats, there were irregular step-ladder patterns of collagen with resorption cavities and several hole sizes. The CSN1S2 protein from goat milk repaired the collagen structure in trabecular bone, as indicated by the reduction in holes and the rearrangement of fibrillar collagen into step-ladder patterns (smooth surfaces). In groups administered CSN1S2 protein from goat yoghurt, the fibrillar collagen and irregular topography of the trabecular bone surface were still observed (**Figure 3**).

## Femur histomorphometry

**Table 3** shows the characteristics of femoral trabecular bone among treated supplementation and control groups. The trabecular thickness and volume were significantly lower in the CM and CY groups as compared to the control group ( $p < 0.05$ ). The trabecular volume was significantly decreased in the CM group relative to the control group ( $p < 0.05$ ). All parameters were not significantly different in the RA, RAM, and RAY groups as compared to the control group ( $p > 0.05$ ). The trabecular thickness was significantly lower, but the other parameters were significantly larger in the CY group relative to the CM group ( $p < 0.05$ ). The trabecular volume was significantly elevated in the RAM and RAY groups relative to the CM group ( $p < 0.05$ ). The trabecular thickness was significantly higher in the RAY group relative to the CM and CY groups ( $p < 0.05$ ). However, all parameters were not significantly different in the RAM or RAY groups as compared to the RA group ( $p < 0.05$ ).

## Discussion

The fermentation process may help improve nutritional profiles. Foods produced through biotechnological processes (such as fermentation) may prevent or at least minimize the risk of lifestyle-related disease.<sup>29</sup> Our findings showed that the CSN1S2 protein from yoghurt (fermentation product) had lower levels of calcium and nickel, but higher phosphorus as compared to the CSN1S2 protein from goat milk. In the scope of bone health, although calcium is one of the main minerals in bones, previous human studies

**Table 2** Femoral-bone mineral content in treated and control (untreated) groups.

Mineral (%)	C	CM	CY	RA	RAM	RAY
Calcium	84.25 ± 1.71	84.50 ± 0.34	82.85 ± 5.83	81.60 ± 3.11	82.95 ± 0.17	83.65 ± 3.05
Phosphorus	10.30 ± 4.06	9.94 ± 1.33	4.95 ± 1.21*	10.85 ± 0.98	11.80 ± 0.92	9.80 ± 1.96**
Chromium	0.65 ± 0.63	0.25 ± 0.14	0.41 ± 0.09	0.66 ± 0.61	0.57 ± 0.48	0.58 ± 0.37
Iron	0.98 ± 0.10	0.85 ± 0.39	1.65 ± 0.63	1.26 ± 0.98	1.16 ± 0.62	1.15 ± 0.39
Nickel	1.05 ± 1.74	0.95 ± 0.76	2.32 ± 2.16	1.54 ± 0.39	1.66 ± 0.83	2.41 ± 0.39
Copper	0.34 ± 0.06	0.22 ± 0.03	0.47 ± 0.05	0.48 ± 0.31	0.43 ± 0.21	0.47 ± 0.09
Zinc	0.75 ± 0.11	0.98 ± 0.60	1.42 ± 0.77	0.75 ± 0.51	0.56 ± 0.30	0.67 ± 0.27
Ytterbium	0.25 ± 0.17	0.15 ± 0.17	0.05 ± 0.05	0.15 ± 0.17	0.35 ± 0.40	0.50 ± 0.57


Data are presented as mean ± standard deviation.

C = control (untreated) group; CFA = complete Freund's adjuvant; CM = group receiving CSN1S2 protein from goat milk; CY = group receiving CSN1S2 protein from goat yoghurt; RA = RHA group; RAM = RHA group receiving CSN1S2 from goat milk; RAY = RHA group receiving CSN1S2 from goat yoghurt; RHA = rheumatoid arthritis.

\*  $p < 0.05$  in comparison with CM group.

\*\*  $p < 0.05$  in comparison with CY group.






**Figure 1** Hydroxyapatite crystal and lattice parameters of femur from CFA-induced RhA in rats. The size of crystal was increased in RhA groups with or without treatment and all control treatment group compared to control group. Blue circle, calcium; red circle, oxygen; and brown circle, phosphorus. C = control (untreated) group; CFA = complete Freund's adjuvant; CM = group receiving CSN1S2 protein from goat milk; CY = group receiving CSN1S2 protein from goat yoghurt; RA = RhA group; RAM = RhA group receiving CSN1S2 from goat milk; RAY = RhA group receiving CSN1S2 from goat yoghurt; RhA = rheumatoid arthritis. <sup>a</sup>: x axis; <sup>b</sup>: y axis; <sup>c</sup>: z axis

showed that there is hypermineralization and higher calcium levels in hydroxyapatite crystal structures from osteoporosis patients.<sup>30,31</sup> This phenomenon encouraged investigation to discover the ideal mineral composition of

food aimed to inhibit osteoporosis and osteoporosis-related disease.

The biological effects of inorganic compounds in processes associated with bone formation and turnover have also been described, leading to findings related to therapies for bone disease and degradation. An example of such therapy is the clinical use of strontium ranelate in patients with osteoporosis.<sup>32</sup> This study discovered several inorganic compounds in the CSN1S2 protein from goat milk and yoghurt, including phosphorus, sodium, calcium, iron, nickel, copper, and ytterbium. Moreover, the CSN1S2 protein from goat yoghurt has higher levels of phosphorus and lower levels of calcium and nickel relative to those observed in the CSN1S2 protein from goat milk. These minerals can be substituted or incorporated into hydroxyapatite crystals of the bone. Subsequently, the composition of minerals in hydroxyapatite crystals determines bone mesostructure and integrity.<sup>33</sup> This study demonstrated that the levels of calcium, chromium, iron, copper, zinc, nickel, and ytterbium were not significantly different between groups ( $p > 0.05$ ). This result may be due to the substitution process that occurs when one of these minerals replaces a comparable atom due to the similarities in their radii and charges.<sup>34</sup> This finding indicates that CFA-induced RhA can cause osteoporosis, but possibly not as a result of changes in mineral concentration. We hypothesized that inflammation in RhA is a trigger of bone resorption. Our previous data found that CFA-induced RhA inflammation may not be interleukin-17 dependent, but rather dependent upon the pro-inflammatory cytokine tumor necrosis factor alpha (TNF- $\alpha$ ), which could activate nuclear factor kappa-B signaling involved in inflammation and apoptosis in bone cells.<sup>35–37</sup>



**Figure 2** The percentage of femoral-bone crystallinity of CFA-induced RhA in rats. Treatment with the CSN1S2 protein from goat milk and increased crystallinity, which is significantly different in the RhA group as compared to the control group. C = control (untreated) group; CFA = complete Freund's adjuvant; CM = group receiving CSN1S2 protein from goat milk; CY = group receiving CSN1S2 protein from goat yoghurt; RA = RhA group; RAM = RhA group receiving CSN1S2 from goat milk; RAY = RhA group receiving CSN1S2 from goat yoghurt; RhA = rheumatoid arthritis. <sup>a</sup>:  $p < 0.05$  in comparison with control group; <sup>b</sup>:  $p < 0.05$  in comparison with CM group; <sup>c</sup>:  $p < 0.05$  in comparison with CY group; <sup>d</sup>:  $p < 0.05$  in comparison with RA group; <sup>e</sup>:  $p < 0.05$  in comparison with RAM group.



CSN1S2 protein from goat milk and yoghurt significantly increased the crystallinity as compared with the control (untreated) or RA groups ( $p < 0.05$ ). Our findings indicated that the CSN1S2 protein from goat milk and yoghurt inhibited the amorphous states of crystals in normal or RhA rats. The highest crystallinity was achieved by yoghurt treatment, which was confirmed by hypergranulation observed in the femur mesostructure. Osteoporosis is an amorphous process caused by an irregular degenerative condition, which is difficult to characterize in the scope of wide ranges of bone mineralization.<sup>33</sup> The growth of minerals in hydroxyapatite crystals occurs under specific orientations, where the c-axis of the crystal is approximately parallel to the length axis of the collagen fiber.<sup>39</sup>

Osteoporosis is characterized by a reduction in bone mass and micro-architectural deterioration of the bone, which increases bone fragility and fractures.<sup>40</sup> Trabecular bone strength is determined not only by the amount of composite material (mineral, protein, and water), but also the distribution of these materials (size, area, and structural properties). A number of properties, such as wall thickness, well-connected trabeculae, and plate-like trabeculae, confer better and stronger trabecular bone properties.<sup>41–43</sup> The trabecular region in the femur or tibia may be the optimal region for detecting such bone loss.<sup>44</sup> SEM of the femoral head of rats from the control (untreated) group showed step-ladder patterns of collagen with granule formations covering the fibrillar collagen. In RhA rats, there were irregular step-ladder patterns of collagen with resorption cavities and several hole sizes, but the levels of trabecular properties were not significantly different in the RA group as compared to the control group ( $p > 0.05$ ). The CSN1S2 protein from goat milk repaired collagen structure in trabecular bone, as indicated by the reduction in holes and the rearrangement of fibrillar collagen into step-ladder patterns (smooth surfaces). In groups administered CSN1S2 protein from goat yoghurt, the fibrillar collagen, irregular topography of trabecular bone surface, and excessive granule formations remained. Excessive granule formation indicated excessive bone formation by osteoblasts. This may have been due to components of yoghurt, such as lactoferrin, angiogenin, and growth-factor binding proteins that contribute to the mitogenic activity of osteoblasts.<sup>45,46</sup>

Based on histomorphometry analysis, the CSN1S2 protein from goat milk was more effective than goat yoghurt in maintaining trabecular thickness in normal rats. The CSN1S2 protein from goat yoghurt increased trabecular number and volume, but induced trabecular spacing. The CSN1S2 protein from goat milk increased the trabecular volume in RhA rats, but reduced the trabecular thickness. Overall, this finding indicated that CFA-induced rheumatoid arthritis in rats induced femur osteoporosis and rearrangement of the trabecular wall. The decrease in trabecular thickness in the control group, but the increase observed in the RAY group, indicated that yoghurt induced trabecular bone turnover. The CSN1S2 protein from goat milk is more effective than that from goat yoghurt in repairing the crystallinity, collagen structure, and trabecular mesostructure.

In conclusion our study suggested that CFA-induced RhA in rats induced femoral bone osteoporosis. The CSN1S2

protein from goat milk was more effective than goat yoghurt at improving femoral bone crystallinity and mesostructure in RhA rats. Therefore, the CSN1S2 protein from goat milk is recommended as a source of bioactive peptides for anti-osteoporosis effects in RhA.

## Conflicts of interest

The authors declare that there are no conflicts of interest.

## Acknowledgments

This study was supported by BOPTN-RU PTN UB decentralization research grant (No. 058/SK/2012) of 2012–2014. The authors thank Laboratory of Physic and Central Laboratory-Faculty of Sciences University of Malang, and Biosains Laboratory of Universitas Brawijaya for providing the SEM equipment and analyses.

## References

1. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. *Arthritis Care Res.* 2012;64:640–647.
2. Roux C. Osteoporosis in inflammatory joint diseases. *Osteoporos Int.* 2011;22:421–433.
3. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. *Arthritis Rheum.* 2000;43:522–530.
4. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. *J Rheumatol.* 2000;27:2582–2589.
5. Shibuya K, Hagino H, Morio Y, et al. Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. *Clin Rheumatol.* 2002;21:150–158.
6. Lane NE, Pressman AR, Star VL, et al. Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. *J Bone Miner Res.* 1995;10:257–263.
7. Huusko TM, Korpela M, Karppi P, et al. Three fold increased risk of hip fractures with rheumatoid arthritis in Central Finland. *Ann Rheum Dis.* 2001;60:521–522.
8. van Staa TP, Geusens P, Bijlsma WJ, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum.* 2006;54:3104–3112.
9. Orstavik RE, Haugeberg G, Uhlig T, et al. Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. *Ann Rheum Dis.* 2004;63:177–182.
10. Dao HH, Do QT, Sakamoto J. Bone mineral density and frequency of osteoporosis among Vietnamese women with early rheumatoid arthritis. *Clin Rheumatol.* 2011;30:1353–1361.
11. Fukuda W, Yamazaki T, Akaogi T, et al. Malnutrition and disease progression in patients with rheumatoid arthritis. *Mod Rheumatol.* 2005;15:104–107.
12. Rall L, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. *Rheumatology.* 2004;43:1219–1223.
13. Sharma S, Singh R, Rana S. Bioactive peptides: a review. *Bioautomation.* 2011;15:223–250.



14. Tidona F, Criscione A, Guastella AM, et al. Bioactive peptide in dairy product. *Ital J Anim Sci.* 2009;8:315–340.
15. Rohmah RN, Widjajanto E, Fatchiyah F. Protective effect of CSN1S2 protein of goat milk on ileum microstructure and inflammation in rat-CFA-induced rheumatoid arthritis. *Asian Pac J Trop Dis.* 2015;5:564–568.
16. Chotimah C, Ciptadi G, Setiawan B, et al. CSN1S2 protein of goat milk inhibits the decrease of viability and increases the proliferation of MC3T3E1 pre-osteoblast cell in methyl glyoxal exposure. *Asian Pac J Trop Dis.* 2015;5:219–223.
17. Fatchiyah F, Hardiyanti F, Widodo N. Selective inhibition on RAGE-binding AGEs required by bioactive peptide alpha-S2 case in protein from goat Ethawah breed milk: study of biological modeling. *Acta Informatica Med.* 2015;23:90–96.
18. Dziuba B, Dziuba M. Milk proteins-derived bioactive peptides in dairy products: molecular, biological and methodological aspects. *Acta Sci Pol Technol Aliment.* 2014;13:5–25.
19. Fuglsang A, Nilsson D, Nyborg NCB. Cardiovascular effects of fermented milk containing angiotensin-converting enzyme inhibitors evaluated in permanently catheterized, spontaneously hypertensive rats. *Appl Environ Microbiol.* 2002;68:3566–3569.
20. Meisel H, FitzGerald RJ. Biofunctional peptides from milk proteins: mineral binding and cytomodulatory effects. *Curr Pharm Des.* 2003;9:1289–1295.
21. Meisel H. Multifunctional peptides encrypted in milk proteins. *Biofactors.* 2004;21:55–61.
22. Bennett LE, Crittenden R, Khoo E, et al. Evaluation of immunomodulatory dairy peptide fractions. *Australian J Dairy Technol.* 2005;60:106–109.
23. Gauthier SF, Pouliot Y, Maubois JL. Growth factors from bovine milk and colostrum : composition, extraction and biological activities. *Lait.* 2006;86:99–125.
24. Budiarti IK, Padaga MC, Fatchiyah F. Nutritional composition and protein profile of goat yogurt PE with double culture between *Streptococcus thermophilus* and *Lactobacillus* species. *Cukurova Med J.* 2013;38:681–686.
25. Shicheng Z, Kunzheng W, Lihing F, et al. The pain-related behavior changes correlate with the bone damage in a rat model of rheumatoid arthritis. *J Med Colleges PLA.* 2013;28:160–173.
26. Noor Z, Setiawan B. Subchronic inhaled particulate matter coal dust changes bone mesostructure, mineral element and turn over markers in rats. *J Exp Integr Med.* 2013;3:153–158.
27. Parfitt AM, Drezner MK, Glorieux FH. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res.* 1987;2:595–610.
28. Doube M, Klosowski MM, Arganda-Carreras I, et al. BoneJ: free and extensible bone image analysis in ImageJ. *Bone.* 2010;47:1076–1079.
29. Mugumura M, Ahmed AM, Kawahara S, et al. A combination of soybean and skimmed milk reduces osteoporosis in rats. *J Funct Foods.* 2012;14:810–818.
30. Busse B, Hahn M, Soltan M, et al. Increased calcium content and inhomogeneity of mineralization render bone toughness in osteoporosis: mineralization, morphology and biomechanics of human single trabeculae. *Bone.* 2009;45:1034–1043.
31. Noor Z, Hidayat M, Rahim AH, et al. Bone microstructure and atomic periodic disharmonization in osteoporosis. *Universa Medicina.* 2012;31:96–104.
32. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. *New Engl J Med.* 2007;357:905–916.
33. Noor Z. Nanohydroxyapatite application to osteoporosis management. *J Osteoporos.* 2013;2013, 679025. <http://dx.doi.org/10.1155/2013/679025>.
34. Noor Z, Setiawan B. Combined inhalation of cigarette smoke and coal dust particulate matter 10 increase bone iron level in rat. *J Exp Integr Med.* 2013;3:69–72.
35. Bia RR, Virginia RP, Setiawan B, et al. Goat milk CSN1S2 is able to decrease the severity scoring, TNF-a, and RAGE expression in complete Freund's adjuvant induced rheumatoid arthritis model of rats. *Biomarkers & Genom Med.* 2015;7:64–71.
36. Osta B, Benedetti G, Miossec P. Classical and paradoxical effects of TNF-alpha on bone homeostasis. *Front Immunol.* 2014;5:48.
37. Horowitz MC, Xi Y, Wilson K, et al. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. *Cytokine Growth Factor Rev.* 2001;12:9–18.
38. Walwadkar SD, Suryakar AN, Katkam RV, et al. Oxidative stress and calcium-phosphorus levels in Rheumatoid arthritis. *Indian J Clin Biochem.* 2006;21:134–137.
39. Vallet-Regi M, Arcos D. *Biomimetic nanoceramics in clinical use: from materials to applications.* 2nd ed. Cambridge: The Royal Society of Chemistry; 2008.
40. Zhao X, Wu Z, Zhang Y, et al. Locally administrated perindopril improves healing in an ovariectomized rat tibial osteotomy model. *PLoS One.* 2012;7:e33228.
41. Bowring CE, Francis RM. National Osteoporosis Society's Position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. *Menopause Int.* 2011;17:63–65.
42. Burrows M, Liu D, Moore S, et al. Bone microstructure at the distal tibia provides a strength advantage to males in late puberty: an HR-pQCT study. *J Bone Miner Res.* 2010;25:1423–1432.
43. Mosekilde L, Ebbesen EN, Tornvig L, et al. Trabecular bone structure and strength - remodelling and repair. *J Musculoskelet Neuronal Interact.* 2000;1:25–30.
44. Toshiaki T, Tsao PW, Totsuka R, et al. Changes in bone mineral density in rat adjuvant arthritis. *Clin Immunol Immunopathol.* 1997;84:166–170.
45. Palmano K, Callon KE, Watson M, et al. *Basic proteins in the lactoferrin fraction augment anabolic bone activity. Proceedings from the Australian and New Zealand Bone and Mineral Society 17<sup>th</sup> Annual Scientific Meeting.* 9–12 September 2007. 2007;78. Queenstown, New Zealand.
46. Palmano KP, Ramos R, Watson M, et al. Survival and bone-active properties of bone lactoferrin supplemented into stirred yoghurt. *Int Dairy J.* 2011;21:477–483.